Rosetta Genomics (NASDAQ: ROSG) and Charles River Laboratories Intl. (NYSE:CRL) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, risk, institutional ownership, analyst recommendations, earnings, profitability and dividends.

Insider & Institutional Ownership

7.5% of Rosetta Genomics shares are held by institutional investors. Comparatively, 97.5% of Charles River Laboratories Intl. shares are held by institutional investors. 2.2% of Charles River Laboratories Intl. shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Rosetta Genomics and Charles River Laboratories Intl., as reported by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Rosetta Genomics 0 1 0 0 2.00
Charles River Laboratories Intl. 0 6 4 0 2.40

Charles River Laboratories Intl. has a consensus price target of $113.80, suggesting a potential upside of 14.06%. Given Charles River Laboratories Intl.’s stronger consensus rating and higher probable upside, analysts plainly believe Charles River Laboratories Intl. is more favorable than Rosetta Genomics.

Valuation & Earnings

This table compares Rosetta Genomics and Charles River Laboratories Intl.’s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Rosetta Genomics $9.23 million 0.32 -$16.23 million ($9.31) -0.05
Charles River Laboratories Intl. $1.68 billion 2.81 $154.76 million $4.10 24.33

Charles River Laboratories Intl. has higher revenue and earnings than Rosetta Genomics. Rosetta Genomics is trading at a lower price-to-earnings ratio than Charles River Laboratories Intl., indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Rosetta Genomics has a beta of 0.34, meaning that its share price is 66% less volatile than the S&P 500. Comparatively, Charles River Laboratories Intl. has a beta of 0.74, meaning that its share price is 26% less volatile than the S&P 500.


This table compares Rosetta Genomics and Charles River Laboratories Intl.’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Rosetta Genomics N/A N/A N/A
Charles River Laboratories Intl. 10.72% 26.58% 8.92%


Charles River Laboratories Intl. beats Rosetta Genomics on 14 of the 14 factors compared between the two stocks.

Rosetta Genomics Company Profile

Rosetta Genomics Ltd. is engaged in developing and commercializing new diagnostic tests based on various genomics markers, including deoxyribonucleic acid (DNA), micro ribonucleic acid (microRNA) and protein biomarkers and using various technologies, including, Quantitative polymerase chain reaction (qPCR), microarrays, Next Generation Sequencing (NGS) and Fluorescence In Situ Hybridization (FISH). It is marketing and selling over four diagnostic tests based on its microRNA technologies, which include RosettaGX Cancer Origin, mi-LUNG, mi-KIDNEY and RosettaGX Reveal. Its therapeutic pipeline consists of the projects, which include Rimonim Consortium and Magneton Project. It focuses on developing diagnostic assay, RosettaGX Reveal V2. It is also focusing on developing Bladder cancer risk stratification. Its PersonalizeDx is focused on the detection of genomic changes through FISH technology, which helps to detect cancer.

Charles River Laboratories Intl. Company Profile

Charles River Laboratories International, Inc. is an early-stage contract research company. The Company is engaged in laboratory animal medicine and science (research model technologies) and develop a portfolio of discovery and safety assessment services, both good laboratory practice (GLP) and non-GLP, which supports its clients from target identification through non-clinical development. The Company operates in three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing). The RMS segment includes Research Models and Research Model Services. The DSA segment includes Discovery Services and Safety Assessment. The Manufacturing segment includes Microbial Solutions, Avian, Biologics and Contract Manufacturing. The Company also provides a suite of products and services to support the Company’s clients’ manufacturing activities.

Receive News & Ratings for Rosetta Genomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rosetta Genomics and related companies with's FREE daily email newsletter.